Gapping up
In reaction to strong earnings/guidance: KMX +4.5%, PERY +4.3%, LL +2.1%, URBN +1.7%, (Urban Outfitters reports thus far 2016 Q1 comparable Retail segment net sales are mid single-digit positive), MU +1.2%, PRGS +1%, ELTK +0.9%
M&A news: LO +3.1% (moving higher in recent trade following speculation that LO / RAI deal will be approved by FTC), SOPW +2.5% (announces the acquisition of 'Aerojet' solar projects), RAI +2.4% (moving higher in recent trade following speculation that LO / RAI deal will be approved by FTC)
Other news: RPPX +19.1% (announced that the New Drug Application for its enclomiphene citrate product candidate, formerly known as Androxal, has been accepted by the FDA), WBAI +17.1% (attributed to speculation of potential restart of China online lottery), KEM +10.7% (purchased IntelliData, a developer of digital solutions; terms not disclosed), TCPI +10.4% (announces that its product validation review is proceeding as expected; discloses a delay in filing its Form 10-K ), HERO +8.8% (signed a five-year contract with a subsidiary of Eni S.p.A. (E) for use of the Hercules 260 in West Africa), FXCM +6.6% (announces it has repaid an additional $54 mln outstanding under credit agreement with Leucadia (LUK); avoids contingent financing fee of $30 mln), ZN +5.8% (co has closed a venture loan to Education Elements, a services and software solution provider that helps districts and schools develop and implement personalized learning strategies), CNDO +4.6% (forms new subsidiary, DiaVax Biosciences, to develop novel immunotherapies for Cytomegalovirus; DiaVax secures rights to two clinical-stage program), RICK +4% (announced an agreement to settle in full a New York based federal wage and hour class action case), CNO +3.7% (to replace SLXP in the S&P MidCap 400), AN +3.3% (reported retail sales of 77,242 new vehicles in the first quarter of 2015, an increase of 10%), TXMD +3.1% (favorable commentary on Wednesday's Mad Money), OMER+2.9% (announces the nationwide commercial availability of Omidria ), XON +2.4% (Intrexon signs cooperative Research and Development agreement with NCI), MDVN +2.4% (announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide), GENE +2% (ongoing vol pre-mkt; rumor of partnership with JNJ yday), RCPT +1.5% (following late surge highs on M&A speculation), WWE +1.4% (reported that WrestleMania 31 broke records for viewership, attendance, social and digital media engagement and merchandise sales), FRPT +1.3% (favorable commentary on Wednesday's Mad Money), ALK +1.3% (provides March operational results), GZT +1.2% (still checking), HLF +1.2% (Pershing Square issues statement responding to WSJ article about Herbalife in China), ALV +1% (following monthly auto sales), HCA +0.9% (favorable commentary on Wednesday's Mad Money)
Analyst comments: WPT +1.8% (upgraded to Buy from Neutral at BofA/Merrill ), TSLA +1.8% (positive Credit Suisse note), FB +0.7% (target raised to $97 from $91 at Citigroup), DKS +0.5% (upgraded to Positive from Neutral at Susquehanna
)
In reaction to strong earnings/guidance: KMX +4.5%, PERY +4.3%, LL +2.1%, URBN +1.7%, (Urban Outfitters reports thus far 2016 Q1 comparable Retail segment net sales are mid single-digit positive), MU +1.2%, PRGS +1%, ELTK +0.9%
M&A news: LO +3.1% (moving higher in recent trade following speculation that LO / RAI deal will be approved by FTC), SOPW +2.5% (announces the acquisition of 'Aerojet' solar projects), RAI +2.4% (moving higher in recent trade following speculation that LO / RAI deal will be approved by FTC)
Other news: RPPX +19.1% (announced that the New Drug Application for its enclomiphene citrate product candidate, formerly known as Androxal, has been accepted by the FDA), WBAI +17.1% (attributed to speculation of potential restart of China online lottery), KEM +10.7% (purchased IntelliData, a developer of digital solutions; terms not disclosed), TCPI +10.4% (announces that its product validation review is proceeding as expected; discloses a delay in filing its Form 10-K ), HERO +8.8% (signed a five-year contract with a subsidiary of Eni S.p.A. (E) for use of the Hercules 260 in West Africa), FXCM +6.6% (announces it has repaid an additional $54 mln outstanding under credit agreement with Leucadia (LUK); avoids contingent financing fee of $30 mln), ZN +5.8% (co has closed a venture loan to Education Elements, a services and software solution provider that helps districts and schools develop and implement personalized learning strategies), CNDO +4.6% (forms new subsidiary, DiaVax Biosciences, to develop novel immunotherapies for Cytomegalovirus; DiaVax secures rights to two clinical-stage program), RICK +4% (announced an agreement to settle in full a New York based federal wage and hour class action case), CNO +3.7% (to replace SLXP in the S&P MidCap 400), AN +3.3% (reported retail sales of 77,242 new vehicles in the first quarter of 2015, an increase of 10%), TXMD +3.1% (favorable commentary on Wednesday's Mad Money), OMER+2.9% (announces the nationwide commercial availability of Omidria ), XON +2.4% (Intrexon signs cooperative Research and Development agreement with NCI), MDVN +2.4% (announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide), GENE +2% (ongoing vol pre-mkt; rumor of partnership with JNJ yday), RCPT +1.5% (following late surge highs on M&A speculation), WWE +1.4% (reported that WrestleMania 31 broke records for viewership, attendance, social and digital media engagement and merchandise sales), FRPT +1.3% (favorable commentary on Wednesday's Mad Money), ALK +1.3% (provides March operational results), GZT +1.2% (still checking), HLF +1.2% (Pershing Square issues statement responding to WSJ article about Herbalife in China), ALV +1% (following monthly auto sales), HCA +0.9% (favorable commentary on Wednesday's Mad Money)
Analyst comments: WPT +1.8% (upgraded to Buy from Neutral at BofA/Merrill ), TSLA +1.8% (positive Credit Suisse note), FB +0.7% (target raised to $97 from $91 at Citigroup), DKS +0.5% (upgraded to Positive from Neutral at Susquehanna
)